Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines
dc.contributor.author | DiGiovine, Bruno | en_US |
dc.contributor.author | Burdick, Marie D. | en_US |
dc.contributor.author | Arenberg, Douglas A. | en_US |
dc.contributor.author | Kunkel, Steven L. | en_US |
dc.contributor.author | Strieter, Robert M. | en_US |
dc.contributor.author | Strom, Scott R. B. | en_US |
dc.contributor.author | Keane, Michael P. | en_US |
dc.contributor.author | Iannettoni, Mark D. | en_US |
dc.date.accessioned | 2006-09-08T19:57:20Z | |
dc.date.available | 2006-09-08T19:57:20Z | |
dc.date.issued | 2000-04 | en_US |
dc.identifier.citation | Arenberg, Douglas A.; Keane, Michael P.; DiGiovine, Bruno; Kunkel, Steven L.; Strom, Scott R. B.; Burdick, Marie D.; Iannettoni, Mark D.; Strieter, Robert M.; (2000). "Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines." Cancer Immunology, Immunotherapy 49(2): 63-70. <http://hdl.handle.net/2027.42/42086> | en_US |
dc.identifier.issn | 0340-7004 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42086 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10823415&dopt=citation | en_US |
dc.description.abstract | Bronchogenic carcinoma is the leading cause of malignancy-related mortality in the United States, with an overall 5-year survival rate of less than 15%. This aggressive behavior reflects, among other traits, the capacity of the tumor to evade normal host immune defenses, and to induce a pro-angiogenic environment. A central feature of any immune response toward tumors is the recruitment of specific immune cell populations. In the present study we investigated the infiltration of monocytes in human specimens of non-small-cell lung cancer (NSCLC). The presence of macrophages in NSCLC tumors was documented by immunohistochemistry. In vitro chemotaxis assays demonstrated higher monocyte chemotactic activity in NSCLC tumor homogenates than in normal lung tissue. We next investigated the expression of CC chemokines within specimens of NSCLC tumors. Levels of the CC chemokines were higher in NSCLC tumor tissue than in normal lung tissue. Immunolocalization showed that the cells associated with antigenic CC chemokines were the malignant tumor cells, as well as occasional stromal cells. Maximal inhibition of monocyte chemotaxis induced by NSCLC in vitro occurred in the presence of neutralizing antibodies to MCP-1 and MIP-1β. On follow-up of 15 patients in whom we quantified macrophage infiltration, we found that those with recurrence of disease had higher levels of macrophage infiltration in their initial tumors. However, the functional significance of CC-chemokine-mediated macrophage infiltration into NSCLC remains to be determined. | en_US |
dc.format.extent | 323161 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | Chemokine | en_US |
dc.subject.other | Tumor | en_US |
dc.subject.other | Key Words Macrophage | en_US |
dc.title | Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Division of Pulmonary and Critical Care, 6301 MSRB III, Box 0642, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA Tel.: +1-734-936-2612 Fax: +1-734-764-4556 e-mail: darenber@umich.edu, US | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Division of Pulmonary and Critical Care, 6301 MSRB III, Box 0642, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA Tel.: +1-734-936-2612 Fax: +1-734-764-4556 e-mail: darenber@umich.edu, US | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Department of Pathology, Ann Arbor, Mich., USA, US | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Department of Surgery, Ann Arbor, Mich., USA, US | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Division of Pulmonary and Critical Care, 6301 MSRB III, Box 0642, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA Tel.: +1-734-936-2612 Fax: +1-734-764-4556 e-mail: darenber@umich.edu, US | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Division of Pulmonary and Critical Care, 6301 MSRB III, Box 0642, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA Tel.: +1-734-936-2612 Fax: +1-734-764-4556 e-mail: darenber@umich.edu, US | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles (UCLA), Los Angeles, Calif., USA, US | en_US |
dc.contributor.affiliationother | Henry Ford Hospital, Division of Pulmonary Medicine, Detroit, Mich., USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 10823415 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42086/1/262-49-2-63_00490063.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002620050603 | en_US |
dc.identifier.source | Cancer Immunology, Immunotherapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.